New developments in lentiviral vector design, production and purification

Expert Opinion on Biological Therapy

Volumn 13, Issue 7, 2013, Pages 987-1011

  Segura, Maria Mercedes ^a   Mangion, Mathias ^b   Gaillet, Bruno ^b   Garnier, Alain ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Gene therapy; Lentiviral vectors; Production; Purification; Vectors design

Indexed keywords

BUTYRIC ACID; CAFFEINE; CALCIUM PHOSPHATE; CHLOROQUINE; LENTIVIRUS VECTOR; LIPID; NUCLEIC ACID; PLASMID DNA; POLYETHYLENEIMINE; RETROVIRUS VECTOR;

AFFINITY CHROMATOGRAPHY; ANION EXCHANGE CHROMATOGRAPHY; BACULOVIRUS; CELL CULTURE; CELL SUSPENSION; CENTRIFUGATION; CLINICAL TRIAL (TOPIC); COLUMN CHROMATOGRAPHY; CONCENTRATION (PARAMETERS); DNA PACKAGING; DOWNSTREAM PROCESSING; ELECTROPORATION; FILTRATION; GEL PERMEATION CHROMATOGRAPHY; GENETIC ENGINEERING; HUMAN; LARGE SCALE PRODUCTION; MEDICAL TECHNOLOGY; PLASMID; PRECIPITATION; PROCESS DEVELOPMENT; PROTEIN DEGRADATION; PURIFICATION; QUALITY CONTROL; REVIEW; SCALE UP; STORAGE; TRANSIENT EXPRESSION; TRANSIENT TRANSFECTION; ULTRAFILTRATION; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION;

ANIMALS; DRUG DESIGN; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LENTIVIRUS;

LENTIVIRUS;

EID: 84878941170     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.779249     Document Type: Review

References (213)

1. Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990;323(9):570-8
2. Wiley J. Gene therapy clinical trials worldwide. 2012. Available from: http://www.wiley.com/legacy/wileychi/genmed/clinical/
3. MacGregor RR. Clinical protocol. A phase 1 open-label clinical trial of the safety and tolerability of single escalating doses of autologous CD4 T cells transduced with VRX496 in HIV-positive subjects. Hum Gene Ther 2001;12(16):2028-9
4. Vogt VM, Simon MN. Mass determination of rous sarcoma virus virions by scanning transmission electron microscopy. J Virol 1999;73(8):7050-5
5. Katz RA, Skalka AM. The retroviral enzymes. Annu Rev Biochem 1994;63:133-73
6. Adamson CS, Jones IM. The molecular basis of HIV capsid assembly-five years of progress. Rev Med Virol 2004;14(2):107-21
7. Jones IM, Morikawa Y. The molecular basis of HIV capsid assembly. Rev Med Virol 1998;8(2):87-95
8. Federico M. From lentiviruses to lentivirus vectors. Methods Mol Biol 2003;229:3-15
9. Watanabe S, Temin HM. Encapsidation sequences for spleen necrosis virus, an avian retrovirus, are between the 5' long terminal repeat and the start of the gag gene. Proc Natl Acad Sci USA 1982;79(19):5986-90
10. Charneau P, Alizon M, Clavel F. A second origin of DNA plus-strand synthesis is required for optimal human immunodeficiency virus replication. J Virol 1992;66(5):2814-20
11. Rattray AJ, Champoux JJ. Plus-strand priming by Moloney murine leukemia virus. The sequence features important for cleavage by RNase H. J Mol Biol 1989;208(3):445-56
12. Pluta K, Kacprzak MM. Use of HIV as a gene transfer vector. Acta Biochim Pol 2009;56(4):531-95
13. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996;272(5259):263-7
14. Hematti P, Hong BK, Ferguson C, et al. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol 2004;2(12):e423
15. Modlich U, Navarro S, Zychlinski D, et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 2009;17(11):1919-28
16. De Meyer SF, Vanhoorelbeke K, Chuah MK, et al. Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor. Blood 2006;107(12):4728-36
17. Quinonez R, Sutton RE. Lentiviral vectors for gene delivery into cells. DNA Cell Biol 2002;21(12):937-51
18. Root DE, Hacohen N, Hahn WC, et al. Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods 2006;3(9):715-19
19. Moffat J, Grueneberg DA, Yang X, et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006;124(6):1283-98
20. Klinghoffer RA, Frazier J, Annis J, et al. A lentivirus-mediated genetic screen identifies dihydrofolate reductase (DHFR) as a modulator of beta-catenin/ GSK3 signaling. PLoS One 2009;4(9):e6892
21. Gomez MC, Pope CE, Kutner RH, et al. Generation of domestic transgenic cloned kittens using lentivirus vectors. Cloning Stem Cells 2009;11(1):167-76
22. Donaldson ZR, Yang SH, Chan AW, Young LJ. Production of germline transgenic prairie voles (Microtus ochrogaster) using lentiviral vectors. Biol Reprod 2009;81(6):1189-95
23. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126(4):663-76
24. Brambrink T, Foreman R, Welstead GG, et al. Sequential expression of pluripotency markers during direct reprogramming of mouse somatic cells. Cell Stem Cell 2008;2(2):151-9
25. Chang CW, Lai YS, Pawlik KM, et al. Polycistronic lentiviral vector for "hit and run" reprogramming of adult skin fibroblasts to induced pluripotent stem cells. Stem Cells 2009;27(5):1042-9
26. Gaillet B, Gilbert R, Broussau S, et al. High-level recombinant protein production in CHO cells using lentiviral vectors and the cumate gene-switch. Biotechnol Bioeng 2010;106(2):203-15
27. Wurm M, Gross B, Sgodda M, et al. Improved lentiviral gene transfer into human embryonic stem cells grown in co-culture with murine feeder and stroma cells. Biol Chem 2011;392(10):887-95
28. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000;288(5466):669-72
29. Wiznerowicz M, Trono D. Harnessing HIV for therapy, basic research and biotechnology. Trends Biotechnol 2005;23(1):42-7
30. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009;326(5954):818-23
31. Jarraya B, Boulet S, Ralph GS, et al. Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Sci Transl Med 2009;1(2):2ra4
32. Bank A, Dorazio R, Leboulch P. A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia. Ann N Y Acad Sci 2005;1054:308-16
33. Mitomo K, Griesenbach U, Inoue M, et al. Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with Sendai virus envelopes. Mol Ther 2010;18(6):1173-82
34. Gu Y, Hou W, Xu C, et al. The enhancement of RNAi against HIV in vitro and in vivo using H-2K(k) protein as a sorting method. J Virol Methods 2012;182(1-2):9-17
35. Neschadim A, Wang JC, Lavie A, Medin JA. Bystander killing of malignant cells via the delivery of engineered thymidine-active deoxycytidine kinase for suicide gene therapy of cancer. Cancer Gene Ther 2012;19(5):320-7
36. D'Costa J, Mansfield SG, Humeau LM. Lentiviral vectors in clinical trials: current status. Curr Opin Mol Ther 2009;11(5):554-64
37. Escors D, Breckpot K. Lentiviral vectors in gene therapy: their current status and future potential. Arch Immunol Ther Exp (Warsz) 2010;58(2):107-19
38. Pacchia AL, Adelson ME, Kaul M, et al. An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins. Virology 2001;282(1):77-86
39. Vigna E, Naldini L. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2000;2(5):308-16
40. Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998;72(12):9873-80
41. Cockrell AS, Ma H, Fu K, et al. A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors. Mol Ther 2006;14(2):276-84
42. Ramezani A, Hawley RG. Generation of HIV-1-based lentiviral vector particles. Curr Protoc Mol Biol 2002;Chapter 16:Unit 16 22
43. Dull T, Zufferey R, Kelly M, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998;72(11):8463-71
44. Riviere L, Darlix JL, Cimarelli A. Analysis of the viral elements required in the nuclear import of HIV-1 DNA. J Virol 2010;84(2):729-39
45. Yilmaz A, Fernandez S, Lairmore MD, Boris-Lawrie K. Coordinate enhancement of transgene transcription and translation in a lentiviral vector. Retrovirology 2006;3:13
46. Real G, Monteiro F, Burger C, Alves PM. Improvement of lentiviral transfer vectors using cis-acting regulatory elements for increased gene expression. Appl Microbiol Biotechnol 2011;91(6):1581-91
47. Dupuy FP, Mouly E, Mesel-Lemoine M, et al. Lentiviral transduction of human hematopoietic cells by HIV-1- and SIV-based vectors containing a bicistronic cassette driven by various internal promoters. J Gene Med 2005;7(9):1158-71
48. Schambach A, Bohne J, Baum C, et al. Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression. Gene Ther 2006;13(7):641-5
49. Higashimoto T, Urbinati F, Perumbeti A, et al. The woodchuck hepatitis virus post-transcriptional regulatory element reduces readthrough transcription from retroviral vectors. Gene Ther 2007;14(17):1298-304
50. Hanawa H, Yamamoto M, Zhao H, et al. Optimized lentiviral vector design improves titer and transgene expression of vectors containing the chicken beta-globin locus HS4 insulator element. Mol Ther 2009;17(4):667-74
51. Oh T, Bajwa A, Jia G, Park F. Lentiviral vector design using alternative RNA export elements. Retrovirology 2007;4:38
52. Cronin J, Zhang XY, Reiser J. Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther 2005;5(4):387-98
53. Coil DA, Miller AD. Phosphatidylserine is not the cell surface receptor for vesicular stomatitis virus. J Virol 2004;78(20):10920-6
54. Kobinger GP, Weiner DJ, Yu QC, Wilson JM. Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat Biotechnol 2001;19(3):225-30
55. Wong LF, Azzouz M, Walmsley LE, et al. Transduction patterns of pseudotyped lentiviral vectors in the nervous system. Mol Ther 2004;9(1):101-11
56. Kang Y, Xie L, Tran DT, et al. Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer. Blood 2005;106(5):1552-8
57. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003;197(5):633-42
58. Di Nunzio F, Piovani B, Cosset FL, et al. Transduction of human hematopoietic stem cells by lentiviral vectors pseudotyped with the RD114-TR chimeric envelope glycoprotein. Hum Gene Ther 2007;18(9):811-20
59. Frecha C, Levy C, Cosset FL, Verhoeyen E. Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy. Mol Ther 2010;18(10):1748-57
60. Sena-Esteves M, Tebbets JC, Steffens S, et al. Optimized large-scale production of high titer lentivirus vector pseudotypes. J Virol Methods 2004;122(2):131-9
61. Kim YS, Wielgosz MM, Hargrove P, et al. Transduction of human primitive repopulating hematopoietic cells with lentiviral vectors pseudotyped with various envelope proteins. Mol Ther 2010;18(7):1310-17
62. Bukrinskaya A. HIV-1 matrix protein: a mysterious regulator of the viral life cycle. Virus Res 2007;124(1-2):1-11
63. Hearps AC, Jans DA. Regulating the functions of the HIV-1 matrix protein. AIDS Res Hum Retroviruses 2007;23(3):341-6
64. Klein KC, Reed JC, Lingappa JR. Intracellular destinies: degradation, targeting, assembly, and endocytosis of HIV Gag. AIDS Rev 2007;9(3):150-61
65. Fiorentini S, Riboldi E, Facchetti F, et al. HIV-1 matrix protein p17 induces human plasmacytoid dendritic cells to acquire a migratory immature cell phenotype. Proc Natl Acad Sci USA 2008;105(10):3867-72
66. Urano E, Aoki T, Futahashi Y, et al. Substitution of the myristoylation signal of human immunodeficiency virus type 1 Pr55Gag with the phospholipase C-delta1 pleckstrin homology domain results in infectious pseudovirion production. J Gen Virol 2008;89(Pt 12):3144-9
67. Wagner R, Graf M, Bieler K, et al. Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors. Hum Gene Ther 2000;11(17):2403-13
68. Aoki T, Shimizu S, Urano E, et al. Improvement of lentiviral vector-mediated gene transduction by genetic engineering of the structural protein Pr55 Gag. Gene Ther 2010;17(9):1124-33
69. Yanez-Munoz RJ, Balaggan KS, MacNeil A, et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 2006;12(3):348-53
70. Philippe S, Sarkis C, Barkats M, et al. Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci USA 2006;103(47):17684-9
71. Apolonia L, Waddington SN, Fernandes C, et al. Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol Ther 2007;15(11):1947-54
72. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003;348(3):255-6
73. Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008;118(9):3143-50
74. Mitchell RS, Beitzel BF, Schroder AR, et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol 2004;2(8):E234
75. Montini E, Cesana D, Schmidt M, et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 2009;119(4):964-75
76. Dropulic B. Lentiviral vectors: their molecular design, safety, and use in laboratory and preclinical research. Hum Gene Ther 2011;22(6):649-57
77. Mates L, Chuah MK, Belay E, et al. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet 2009;41(6):753-61
78. VandenDriessche T, Ivics Z, Izsvak Z, Chuah MK. Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells. Blood 2009;114(8):1461-8
79. Staunstrup NH, Moldt B, Mates L, et al. Hybrid lentivirus-transposon vectors with a random integration profile in human cells. Mol Ther 2009;17(7):1205-14
80. Cathomen T, Joung JK. Zinc-finger nucleases: the next generation emerges. Mol Ther 2008;16(7):1200-7
81. Dreyer AK, Cathomen T. Zinc-finger nucleases-based genome engineering to generate isogenic human cell lines. Methods Mol Biol 2012;813:145-56
82. Lombardo A, Genovese P, Beausejour CM, et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol 2007;25(11):1298-306
83. Ni Y, Sun S, Oparaocha I, et al. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector. J Gene Med 2005;7(6):818-34
84. Qi P, Han J, Lu Y, et al. A transient three-plasmid expression system for the production of hepatocytes targeting retroviral vectors. Acta Biochim Biophys Sin (Shanghai) 2007;39(8):567-74
85. Stacey GN, Merten OW. Host cells and cell banking. Methods Mol Biol 2011;737:45-88
86. Segura MM, Garnier A, Durocher Y, et al. Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affinity chromatography purification. Biotechnol Bioeng 2007;98(4):789-99
87. Van Craenenbroeck K, Vanhoenacker P, Haegeman G. Episomal vectors for gene expression in mammalian cells. Eur J Biochem 2000;267(18):5665-78
88. Gama-Norton L, Botezatu L, Herrmann S, et al. Lentivirus production is influenced by SV40 large T-antigen and chromosomal integration of the vector in HEK293 cells. Hum Gene Ther 2011;22(10):1269-79
89. Ansorge S, Lanthier S, Transfiguracion J, et al. Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures. J Gene Med 2009;11(10):868-76
90. Diaz RM, Bateman A, Emiliusen L, et al. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy. Gene Ther 2000;7(19):1656-63
91. Merten OW, Charrier S, Laroudie N, et al. Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum Gene Ther 2011;22(3):343-56
92. Witting SR, Li LH, Jasti A, et al. Efficient large volume lentiviral vector production using flow electroporation. Hum Gene Ther 2012;23(2):243-9
93. Lesch HP, Laitinen A, Peixoto C, et al. Production and purification of lentiviral vectors generated in 293T suspension cells with baculoviral vectors. Gene Ther 2011;18(6):531-8
94. Kutner RH, Puthli S, Marino MP, Reiser J. Simplified production and concentration of HIV-1-based lentiviral vectors using HYPERFlask vessels and anion exchange membrane chromatography. BMC Biotechnol 2009;9:10
95. Kuroda H, Marino MP, Kutner RH, Reiser J. Production of lentiviral vectors in protein-free media. Curr Protoc Cell Biol 2011;Chapter 26:Unit 26 8
96. Tiscornia G, Singer O, Verma IM. Production and purification of lentiviral vectors. Nat Protoc 2006;1(1):241-5
97. Giry-Laterriere M, Verhoeyen E, Salmon P. Lentiviral vectors. Methods Mol Biol 2011;737:183-209
98. Segura MM, Garnier A, Durocher Y, et al. New protocol for lentiviral vector mass production. Methods Mol Biol 2010;614:39-52
99. al Yacoub N, Romanowska M, Haritonova N, Foerster J. Optimized production and concentration of lentiviral vectors containing large inserts. J Gene Med 2007;9(7):579-84
100. Kutner RH, Zhang XY, Reiser J. Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat Protoc 2009;4(4):495-505
101. Jordan M, Kohne C, Wurm FM. Calcium-phosphate mediated DNA transfer into HEK-293 cells in suspension: control of physicochemical parameters allows transfection in stirred media. Transfection and protein expression in mammalian cells. Cytotechnology 1998;26(1):39-47
102. Shin KJ, Wall EA, Zavzavadjian JR, et al. A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression. Proc Natl Acad Sci USA 2006;103(37):13759-64
103. Kosaka Y, Kobayashi N, Fukazawa T, et al. Lentivirus-based gene delivery in mouse embryonic stem cells. Artif Organs 2004;28(3):271-7
104. Coleman JE, Huentelman MJ, Kasparov S, et al. Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo. Physiol Genomics 2003;12(3):221-8
105. Kuroda H, Kutner RH, Bazan NG, Reiser J. Simplified lentivirus vector production in protein-free media using polyethylenimine-mediated transfection. J Virol Methods 2009;157(2):113-21
106. Toledo JR, Prieto Y, Oramas N, Sanchez O. Polyethylenimine-Based Transfection Method as a Simple and Effective Way to Produce Recombinant Lentiviral Vectors. Appl Biochem Biotechnol 2009;157(3):538-44
107. Reed SE, Staley EM, Mayginnes JP, et al. Transfection of mammalian cells using linear polyethylenimine is a simple and effective means of producing recombinant adeno-associated virus vectors. J Virol Methods 2006;138(1-2):85-98
108. Rols MP, Coulet D, Teissie J. Highly efficient transfection of mammalian cells by electric field pulses. Application to large volumes of cell culture by using a flow system. Eur J Biochem 1992;206(1):115-21
109. Li LH, Shivakumar R, Feller S, et al. Highly efficient, large volume flow electroporation. Technol Cancer Res Treat 2002;1(5):341-50
110. Aucoin MG, Mena JA, Kamen AA. Bioprocessing of baculovirus vectors: a review. Curr Gene Ther 2010;10(3):174-86
111. Kost TA, Condreay JP. Recombinant baculoviruses as expression vectors for insect and mammalian cells. Curr Opin Biotechnol 1999;10(5):428-33
112. Poomputsa K, Kittel C, Egorov A, et al. Generation of recombinant influenza virus using baculovirus delivery vector. J Virol Methods 2003;110(1):111-14
113. Cheshenko N, Krougliak N, Eisensmith RC, Krougliak VA. A novel system for the production of fully deleted adenovirus vectors that does not require helper adenovirus. Gene Ther 2001;8(11):846-54
114. Sollerbrant K, Elmen J, Wahlestedt C, et al. A novel method using baculovirus-mediated gene transfer for production of recombinant adeno-associated virus vectors. J Gen Virol 2001;82(Pt 9):2051-60
115. Chen YH, Wu JC, Wang KC, et al. Baculovirus-mediated production of HDV-like particles in BHK cells using a novel oscillating bioreactor. J Biotechnol 2005;118(2):135-47
116. Lesch HP, Turpeinen S, Niskanen EA, et al. Generation of lentivirus vectors using recombinant baculoviruses. Gene Ther 2008;15(18):1280-6
117. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369(9580):2161-70
118. Broussau S, Jabbour N, Lachapelle G, et al. Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture. Mol Ther 2008;16(3):500-7
119. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996;272(5259):263-7
120. Stewart HJ, Fong-Wong L, Strickland I, et al. A stable producer cell line for the manufacture of a lentiviral vector for gene therapy of Parkinson's disease. Hum Gene Ther 2011;22(3):357-69
121. Stewart HJ, Leroux-Carlucci MA, Sion CJ, et al. Development of inducible EIAV-based lentiviral vector packaging and producer cell lines. Gene Ther 2009;16(6):805-14
122. Ikeda Y, Takeuchi Y, Martin F, et al. Continuous high-titer HIV-1 vector production. Nat Biotechnol 2003;21(5):569-72
123. Lee CL, Chou M, Dai B, et al. Construction of stable producer cells to make high-titer lentiviral vectors for dendritic cell-based vaccination. Biotechnol Bioeng 2012;109(6):1551-60
124. Throm RE, Ouma AA, Zhou S, et al. Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood 2009;113(21):5104-10
125. Farson D, Witt R, McGuinness R, et al. A new-generation stable inducible packaging cell line for lentiviral vectors. Hum Gene Ther 2001;12(8):981-97
126. Kong D, Gentz R, Zhang J. Long-term stable production of monocyte-colony inhibition factor (M-CIF) from CHO microcarrier perfusion cultures. Cytotechnology 1998;26(2):131-8
127. Hu X, Xiao C, Huang Z, et al. Pilot production of u-PA with porous microcarrier cell culture. Cytotechnology 2000;33(1-3):13-19
128. Rourou S, van der Ark A, Majoul S, et al. A novel animal-component-free medium for rabies virus production in Vero cells grown on Cytodex 1 microcarriers in a stirred bioreactor. Appl Microbiol Biotechnol 2009;85(1):53-63
129. Trabelsi K, Rourou S, Loukil H, et al. Optimization of virus yield as a strategy to improve rabies vaccine production by Vero cells in a bioreactor. J Biotechnol 2006;121(2):261-71
130. Rourou S, van der Ark A, van der Velden T, Kallel H. A microcarrier cell culture process for propagating rabies virus in Vero cells grown in a stirred bioreactor under fully animal component free conditions. Vaccine 2007;25(19):3879-89
131. Genzel Y, Olmer RM, Schafer B, Reichl U. Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media. Vaccine 2006;24(35-36):6074-87
132. Wu SC, Huang GY, Liu JH. Production of retrovirus and adenovirus vectors for gene therapy: a comparative study using microcarrier and stationary cell culture. Biotechnol Prog 2002;18(3):617-22
133. Davie JR. Inhibition of histone deacetylase activity by butyrate. J Nutr 2003;133(7 Suppl):2485S-93S
134. Kafri T, van Praag H, Ouyang L, et al. A packaging cell line for lentivirus vectors. J Virol 1999;73(1):576-84
135. Karolewski BA, Watson DJ, Parente MK, Wolfe JH. Comparison of transfection conditions for a lentivirus vector produced in large volumes. Hum Gene Ther 2003;14(14):1287-96
136. Jaalouk DE, Crosato M, Brodt P, Galipeau J. Inhibition of histone deacetylation in 293GPG packaging cell line improves the production of self-inactivating MLV-derived retroviral vectors. Virol J 2006;3:27
137. Wibo M, Poole B. Protein degradation in cultured cells. II. The uptake of chloroquine by rat fibroblasts and the inhibition of cellular protein degradation and cathepsin B1. J Cell Biol 1974;63(2 Pt 1):430-40
138. Luthman H, Magnusson G. High efficiency polyoma DNA transfection of chloroquine treated cells. Nucleic Acids Res 1983;11(5):1295-308
139. Ciftci K, Levy RJ. Enhanced plasmid DNA transfection with lysosomotropic agents in cultured fibroblasts. Int J Pharm 2001;218(1-2):81-92
140. Ellis BL, Potts PR, Porteus MH. Creating higher titer lentivirus with caffeine. Hum Gene Ther 2011;22(1):93-100
141. Schweizer M, Merten OW. Large-scale production means for the manufacturing of lentiviral vectors. Curr Gene Ther 2010;10(6):474-86
142. Segura MM, Kamen A, Garnier A. Downstream processing of oncoretroviral and lentiviral gene therapy vectors. Biotechnol Adv 2006;24(3):321-37
143. Wolff M, Reichl U. Downstream processing of cell culture-derived virus particles. Expert Rev Vaccines 2011;10(10):1451-75
144. Andreadis ST, Roth CM, Le Doux JM, et al. Large-scale processing of recombinant retroviruses for gene therapy. Biotechnol Prog 1999;15(1):1-11
145. Rodrigues T, Carrondo MJ, Alves PM, Cruz PE. Purification of retroviral vectors for clinical application: biological implications and technological challenges. J Biotechnol 2007;127(3):520-41
146. Morenweiser R. Downstream processing of viral vectors and vaccines. Gene Ther 2005;12(Suppl 1):S103-10
147. Segura MM, Kamen AA, Garnier A. Overview of current scalable methods for purification of viral vectors. Methods Mol Biol 2011;737:89-116
148. Reeves L, Cornetta K. Clinical retroviral vector production: step filtration using clinically approved filters improves titers. Gene Ther 2000;7(23):1993-8
149. Segura MM, Kamen A, Trudel P, Garnier A. A novel purification strategy for retrovirus gene therapy vectors using heparin affinity chromatography. Biotechnol Bioeng 2005;90(4):391-404
150. Slepushkin V, Chang N, Cohen R, et al. Large-scale purification of a lentiviral vector by size exclusion chromatography or mustang Q ion exchange capsule. Bioprocessing J 2003;2:89-95
151. Ausubel L, Hall C, Sharma A, et al. Production of cGMP-Grade Lentiviral Vectors. Bio Process Int 2012;10(2):32-43
152. Burns JC, Friedmann T, Driever W, et al. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 1993;90(17):8033-7
153. Cooper AR, Patel S, Senadheera S, et al. Highly efficient large-scale lentiviral vector concentration by tandem tangential flow filtration. J Virol Methods 2011;177(1):1-9
154. Geraerts M, Michiels M, Baekelandt V, et al. Upscaling of lentiviral vector production by tangential flow filtration. J Gene Med 2005;7(10):1299-310
155. Scherr M, Battmer K, Eder M, et al. Efficient gene transfer into the CNS by lentiviral vectors purified by anion exchange chromatography. Gene Ther 2002;9(24):1708-14
156. Zimmermann K, Scheibe O, Kocourek A, et al. Highly efficient concentration of lenti- and retroviral vector preparations by membrane adsorbers and ultrafiltration. BMC Biotechnol 2011;11(1):55
157. Cheeks MC, Kamal N, Sorrell A, et al. Immobilized metal affinity chromatography of histidine-tagged lentiviral vectors using monolithic adsorbents. J Chromatogr A 2009;1216(13):2705-11
158. Jungbauer A, Hahn R. Polymethacrylate monoliths for preparative and industrial separation of biomolecular assemblies. J Chromatogr A 2008;1184(1-2):62-79
159. Stadler J, Lemmens R, Nyhammar T. Plasmid DNA purification. J Gene Med 2004;6(Suppl 1):S54-66
160. Kramberger P, Peterka M, Boben J, et al. Short monolithic columns-a breakthrough in purification and fast quantification of tomato mosaic virus. J Chromatogr A 2007;1144(1):143-9
161. Yamada K, McCarty DM, Madden VJ, Walsh CE. Lentivirus vector purification using anion exchange HPLC leads to improved gene transfer. Biotechniques 2003;34(5):1074-8; 80
162. Slepushkin V. Chromatography Methods for Purification of Lentiviral Vectors. 2011.Available from: http:// biotechexpertsnet/wordpress/?p=59
163. Rodrigues T, Alves A, Lopes A, et al. Removal of envelope protein-free retroviral vectors by anion-exchange chromatography to improve product quality. J Sep Sci 2008;31(20):3509-18
164. Eriksson K, Ljunglof A, Rodrigo G, Brekkan E. MAb contaminant removal with a multimodal anion exchanger: a platform step to follow protein A. Bioprocess Int 2009;7:52-6
165. Vazquez-Rey M, Lang DA. Aggregates in monoclonal antibody manufacturing processes. Biotechnol Bioeng 2011;108(7):1494-508
166. Yu JH, Schaffer DV. Selection of novel vesicular stomatitis virus glycoprotein variants from a peptide insertion library for enhanced purification of retroviral and lentiviral vectors. J Virol 2006;80(7):3285-92
167. Chen R, Folarin N, Ho VH, et al. Affinity recovery of lentivirus by diaminopelargonic acid mediated desthiobiotin labelling. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878(22):1939-45
168. Segura MM, Kamen A, Lavoie MC, Garnier A. Exploiting heparin-binding properties of MoMLV-based retroviral vectors for affinity chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2007;846(1-2):124-31
169. Ye K, Jin S, Ataai MM, et al. Tagging retrovirus vectors with a metal binding peptide and one-step purification by immobilized metal affinity chromatography. J Virol 2004;78(18):9820-7
170. Nesbeth D, Williams SL, Chan L, et al. Metabolic biotinylation of lentiviral pseudotypes for scalable paramagnetic microparticle-dependent manipulation. Mol Ther 2006;13(4):814-22
171. Kalbfuss B, Wolff M, Morenweiser R, Reichl U. Purification of cell culture-derived human influenza A virus by size-exclusion and anion-exchange chromatography. Biotechnol Bioeng 2007;96(5):932-44
172. Huyghe BG, Liu X, Sutjipto S, et al. Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum Gene Ther 1995;6(11):1403-16
173. Sastry L, Xu Y, Cooper R, et al. Evaluation of plasmid DNA removal from lentiviral vectors by benzonase treatment. Hum Gene Ther 2004;15(2):221-6
174. Carmo M, Alves A, Rodrigues AF, et al. Stabilization of gammaretroviral and lentiviral vectors: from production to gene transfer. J Gene Med 2009;11(8):670-8
175. Schonely K, Afable C, Slepushkin V, et al. QC release testing of an HIV-1 based lentiviral vector lot and transduced cellular product. Bioprocessing J 2003;2:39-47
176. Agency EEM. Guideline on development and manufacture of lentiviral vectors. CHMPBWP245803; 2005
177. Santos S, Obukhov Y, Nekhai S, et al. Virus-producing cells determine the host protein profiles of HIV-1 virion cores. Retrovirology 2012;9:65
178. Chertova E, Chertov O, Coren LV, et al. Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages. J Virol 2006 Sep;80(18):9039-52
179. Segura MM, Garnier A, Di Falco MR, et al. Identification of host proteins associated with retroviral vector particles by proteomic analysis of highly purified vector preparations. J Virol 2008;82(3):1107-17
180. Denard J, Rundwasser S, Laroudie N, et al. Quantitative proteomic analysis of lentiviral vectors using 2-DE. Proteomics 2009;9(14):3666-76
181. Wheeler JX, Jones C, Thorpe R, Zhao Y. Proteomics analysis of cellular components in lentiviral vector production using Gel-LC-MS/MS. Proteomics Clin Appl 2007;1(2):224-30
182. Muriaux D, Mirro J, Harvin D, Rein A. RNA is a structural element in retrovirus particles. Proc Natl Acad Sci USA 2001;98(9):5246-51
183. Valley-Omar Z, Meyers AE, Shephard EG, et al. Abrogation of contaminating RNA activity in HIV-1 Gag VLPs. Virol J 2011;8:462
184. Geraerts M, Willems S, Baekelandt V, et al. Comparison of lentiviral titration methods. BMS Biotechnol 2006;6:34
185. Fan Y, Luo Y, Chen X, et al. Generation of Human beta-thalassemia Induced Pluripotent Stem Cells from Amniotic Fluid Cells Using a Single Excisable Lentiviral Stem Cell Cassette. J Reprod Dev 2012;58(4):404-9
186. Somers A, Jean JC, Sommer CA, et al. Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette. Stem Cells 2010;28(10):1728-40
187. Sommer CA, Stadtfeld M, Murphy GJ, et al. Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells 2009;27(3):543-9
188. Liang X, Fujioka K, Tsuda Y, et al. Construction of a photo-switchable gene for turning on and off gene expression with light irradiation. Nucleic Acids Symp Ser (Oxf) 2008(52):19-20
189. Liu M, Komiyama M, Asanuma H. Design of light-switchable phage promoter for efficient photo-regulation of gene-expression. Nucleic Acids Symp Ser (Oxf) 2005(49):283-4
190. Shimizu-Sato S, Huq E, Tepperman JM, Quail PH. A light-switchable gene promoter system. Nat Biotechnol 2002;20(10):1041-4
191. Quail PH. Phytochrome-interacting factors. Semin Cell Dev Biol 2000;11(6):457-66
192. Martinez-Garcia JF, Huq E, Quail PH. Direct targeting of light signals to a promoter element-bound transcription factor. Science 2000;288(5467):859-63
193. Nie Z, Bren GD, Vlahakis SR, et al. Human immunodeficiency virus type 1 protease cleaves procaspase 8 in vivo. J Virol 2007;81(13):6947-56
194. Nie Z, Phenix BN, Lum JJ, et al. HIV-1 protease processes procaspase 8 to cause mitochondrial release of cytochrome c, caspase cleavage and nuclear fragmentation. Cell Death Differ 2002;9(11):1172-84
195. Choi SS, Rhee WJ, Kim EJ, Park TH. Enhancement of recombinant protein production in Chinese hamster ovary cells through anti-apoptosis engineering using 30Kc6 gene. Biotechnol Bioeng 2006;95(3):459-67
196. Vieira HL, Pereira AC, Peixoto CC, et al. Improvement of recombinant protein production by an anti-apoptotic protein from hemolymph of Lonomia obliqua. Cytotechnology 2010;62(6):547-55
197. Majors BS, Betenbaugh MJ, Pederson NE, Chiang GG. Enhancement of transient gene expression and culture viability using Chinese hamster ovary cells overexpressing Bcl-x(L). Biotechnol Bioeng 2008;101(3):567-78
198. Figueroa B Jr, Ailor E, Osborne D, et al. Enhanced cell culture performance using inducible anti-apoptotic genes E1B-19K and Aven in the production of a monoclonal antibody with Chinese hamster ovary cells. Biotechnol Bioeng 2007;97(4):877-92
199. Majors BS, Betenbaugh MJ, Pederson NE, Chiang GG. Mcl-1 overexpression leads to higher viabilities and increased production of humanized monoclonal antibody in Chinese hamster ovary cells. Biotechnol Prog 2009;25(4):1161-8
200. Wang XH, Xu J, Zhang Y, et al. Inducible expression of Bcl-XL inhibits sodium butyrate-induced apoptosis in hybridoma, resulting in enhanced antibody production. Cell Biol Int 2004;28(3):185-91
201. Warner TG. Enhancing therapeutic glycoprotein production in Chinese hamster ovary cells by metabolic engineering endogenous gene control with antisense DNA and gene targeting. Glycobiology 1999;9(9):841-50
202. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124(3):471-84
203. Zhao X, Guo J, Yu Y, et al. Overexpression of survivin and cyclin D1 in CHO cells confers apoptosis resistance and enhances growth in serum-free suspension culture. Biotechnol Lett 2011;33(7):1293-300
204. Ye K, Dhiman HK, Suhan J, Schultz JS. Effect of pH on infectivity and morphology of ecotropic moloney murine leukemia virus. Biotechnol Prog 2003;19(2):538-43
205. Le Doux JM, Davis HE, Morgan JR, Yarmush ML. Kinetics of retrovirus production and decay. Biotechnol Bioeng 1999;63(6):654-62
206. Beer C, Meyer A, Muller K, Wirth M. The temperature stability of mouse retroviruses depends on the cholesterol levels of viral lipid shell and cellular plasma membrane. Virology 2003;308(1):137-46
207. Coroadinha AS, Silva AC, Pires E, et al. Effect of osmotic pressure on the production of retroviral vectors: enhancement in vector stability. Biotechnol Bioeng 2006;94(2):322-9
208. Kotani H, Newton PB III, Zhang S, et al. Improved methods of retroviral vector transduction and production for gene therapy. Hum Gene Ther 1994;5(1):19-28
209. Merten OW. State-of-the-art of the production of retroviral vectors. J Gene Med 2004;6(Suppl 1):S105-24
210. Rodrigues AF, Amaral AI, Verissimo V, et al. Adaptation of retrovirus producer cells to serum deprivation: implications in lipid biosynthesis and vector production. Biotechnol Bioeng 2012;109(5):1269-79
211. Coroadinha AS, Ribeiro J, Roldao A, et al. Effect of medium sugar source on the production of retroviral vectors for gene therapy. Biotechnol Bioeng 2006;94(1):24-36
212. Li P, Xu L, Mou Y, et al. Medium Optimization for Exopolysaccharide Production in Liquid Culture of Endophytic Fungus Berkleasmium sp. Dzf12. Int J Mol Sci 2012;13(9):11411-26
213. Yao CL, Chu IM, Hsieh TB, Hwang SM. A systematic strategy to optimize ex vivo expansion medium for human hematopoietic stem cells derived from umbilical cord blood mononuclear cells. Exp Hematol 2004;32(8):720-7